Understanding the Inflammation Connection

For⁤ years, psoriasis⁣ and hidradenitis suppurativa (HS) where primarily viewed‍ as immune-mediated diseases. However, a deeper understanding of their pathophysiology ⁤reveals a ‍strong connection to systemic inflammation, particularly that driven by obesity and metabolic dysfunction. ‍ This isn’t to say these are *simply* metabolic diseases,but that metabolic factors significantly exacerbate and contribute ⁣to disease activity.

Obesity ‍is characterized by chronic, low-grade inflammation. Adipose tissue, especially visceral fat, isn’t ⁣merely ⁢a storage depot; it’s an active endocrine organ releasing pro-inflammatory cytokines like TNF-α, IL-6, and leptin. These cytokines disrupt immune regulation and‍ contribute‍ to‍ insulin resistance, creating a vicious cycle of inflammation and metabolic imbalance.

In psoriasis, this inflammatory milieu amplifies the immune response in the skin, leading to increased ‍keratinocyte proliferation and the characteristic plaques. Similarly, in ⁢HS, inflammation contributes to the development of painful nodules and abscesses in areas rich‍ in apocrine glands.

GLP-1 Agonists: Beyond Diabetes and Weight Loss

Glucagon-like peptide-1 (GLP-1) agonists were originally developed ⁢to treat type 2‍ diabetes⁢ by enhancing insulin secretion and suppressing glucagon release. However, they also promote‍ weight loss and, importantly, possess anti-inflammatory⁤ properties.

GLP-1 receptors are found not onyl in the pancreas but also in immune cells, including T ⁤cells and macrophages. Activation of these receptors can modulate ⁤immune function, reducing the⁢ production of pro-inflammatory cytokines. this dual action – weight loss *and* inflammation reduction – is what makes GLP-1 agonists particularly intriguing ⁣for psoriasis and HS.

Several studies have demonstrated improvements in psoriasis severity with⁤ GLP-1⁣ agonist ⁤use, even autonomous of ⁣weight loss. While the exact mechanisms are still⁤ being investigated, it’s believed that the direct anti-inflammatory effects ⁢on immune cells play a important ⁣role.

Evidence Supporting GLP-1 agonist Consideration

The link between ⁤obesity, ‍inflammation, and these skin conditions⁣ is becoming increasingly clear. Experts now suggest that GLP-1 agonists should be considered as part of a multifaceted treatment approach, ‍particularly for patients with psoriasis or HS who also have obesity or metabolic syndrome.

This isn’t about replacing existing therapies, such as ⁣topical treatments, biologics, or antibiotics. rather, it’s about addressing a basic underlying driver of disease – ⁢chronic inflammation. Combining GLP-1 agonists with conventional treatments may lead to synergistic benefits and improved patient outcomes.